Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo R, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K. Sarian LO, et al. J Med Screen. 2005;12(3):142-9. doi: 10.1258/0969141054855328. J Med Screen. 2005. PMID: 16156945
Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study.
Longatto-Filho A, Erzen M, Branca M, Roteli-Martins C, Naud P, Derchain SF, Hammes L, Sarian LO, Bragança JF, Matos J, Gontijo R, Lima T, Maeda MY, Tatti S, Syrjänen S, Dores G, Lörincz A, Syrjänen K. Longatto-Filho A, et al. Int J Gynecol Cancer. 2006 May-Jun;16(3):955-62. doi: 10.1111/j.1525-1438.2006.00582.x. Int J Gynecol Cancer. 2006. PMID: 16803469
Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K. Derchain SF, et al. J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061. J Med Screen. 2008. PMID: 18573778
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S; NIS Study Research Group; LAMS Study Research Group. Syrjänen K, et al. Eur J Gynaecol Oncol. 2012;33(1):5-14. Eur J Gynaecol Oncol. 2012. PMID: 22439398
Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohort.
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Hammes LS, Podistov J, Costa S, Syrjänen S; NIS Study Research Group; LAMS Study Research Group. Syrjänen K, et al. Eur J Gynaecol Oncol. 2012;33(4):341-52. Eur J Gynaecol Oncol. 2012. PMID: 23091888
Conventional Pap smear and liquid-based cytology as screening tools in low-resource settings in Latin America: experience of the Latin American screening study.
Longatto-Filho A, Maeda MY, Erzen M, Branca M, Roteli-Martins C, Naud P, Derchain SF, Hammes L, Matos J, Gontijo R, Sarian LO, Lima TP, Tatti S, Syrjänen S, Syrjänen K. Longatto-Filho A, et al. Acta Cytol. 2005 Sep-Oct;49(5):500-6. doi: 10.1159/000326195. Acta Cytol. 2005. PMID: 16334026 Clinical Trial.
Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study.
Gontijo RC, Derchain SF, Roteli-Martins C, Bragança JF, Sarian LO, Morais SS, Maeda MY, Longatto-Filho A, Syrjänen KJ. Gontijo RC, et al. Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):239-46. doi: 10.1016/j.ejogrb.2006.05.012. Epub 2006 Jun 30. Eur J Obstet Gynecol Reprod Biol. 2007. PMID: 16814450
Increased risk of oncogenic human papillomavirus infections and incident high-grade cervical intraepithelial neoplasia among smokers: experience from the Latin American screening study.
Sarian LO, Hammes LS, Longatto-Filho A, Guarisi R, Derchain SF, Roteli-Martins C, Naud P, Erzen M, Branca M, Tatti S, de Matos JC, Gontijo R, Maeda MY, Lima T, Costa S, Syrjänen S, Syrjänen K. Sarian LO, et al. Sex Transm Dis. 2009 Apr;36(4):241-8. doi: 10.1097/OLQ.0b013e3181935a7d. Sex Transm Dis. 2009. PMID: 19265732
Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN.
Longatto-Filho A, Hammes LS, Sarian LO, Roteli-Martins C, Derchain SF, Eržen M, Branca M, Tatti S, Naud P, de Matos JC, Gontijo R, Maeda MY, Lima T, Costa S, Syrjänen S, Syrjänen K. Longatto-Filho A, et al. Gynecol Obstet Invest. 2011;71(2):93-103. doi: 10.1159/000320742. Epub 2010 Dec 9. Gynecol Obstet Invest. 2011. PMID: 21150159 Free article. Clinical Trial.
63 results